Zymergen Inc. (NASDAQ: ZY) stock fell -0.77% on Friday to $2.57 against a previous-day closing price of $2.59. With 1.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.52 million shares. During the session, the Specialty Chemicals company that operates in wider Basic Materials sector, reached to the highest price of $2.8200 whereas the lowest price it dropped to was $2.5304. The 52-week range on ZY shows that it touched its highest point at $14.43 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $2.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZY was down-trending over the past week, with a drop of -6.55%, but this was up by 7.08% over a month. Three-month performance surged to 97.69% while six-month performance fell -28.61%. The stock lost -80.76% in the past year, while it has lost -61.58% so far this year. A look at the trailing 12-month EPS for ZY yields -3.54 with Next year EPS estimates of -2.46. For the next quarter, that number is -0.66. This implies an EPS growth rate of -82.10% for this year and 15.50% for next year.
Float and Shares Shorts:
At present, 103.48 million ZY shares are outstanding with a float of 97.57 million shares on hand for trading. On Jul 14, 2022, short shares totaled 3.41 million, which was 3.31% higher than short shares on Jun 14, 2022. In addition to Mr. Jay T. Flatley as the firm’s Chairman & Acting CEO, Mr. Zachariah Serber Ph.D. serves as its Co-Founder, Chief Science Officer & Director.
Through their ownership of 69.04% of ZY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 4.24% of ZY, in contrast to 13.85% held by mutual funds. Shares owned by individuals account for 13.62%. As the largest shareholder in ZY with 4.88% of the stake, GIC Pte Ltd. holds 5,078,902 shares worth 5,078,902. A second-largest stockholder of ZY, ARK Investment Management LLC, holds 3,456,518 shares, controlling over 3.32% of the firm’s shares. Baillie Gifford & Co. is the third largest shareholder in ZY, holding 2,821,956 shares or 2.71% stake. With a 7.25% stake in ZY, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 7,548,035 shares are owned by the mutual fund manager. The Scottish Mortgage Investment Trus, which owns about 2.13% of ZY stock, is the second-largest Mutual Fund holder. It holds 2,212,775 shares valued at 5.24 million. Vanguard Total Stock Market Index holds 1.51% of the stake in ZY, owning 1,572,621 shares worth 3.73 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZY since 3 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZY analysts setting a high price target of $2.60 and a low target of $2.60, the average target price over the next 12 months is $2.60. Based on these targets, ZY could surge 1.17% to reach the target high and rise by 1.17% to reach the target low. Reaching the average price target will result in a growth of 1.17% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ZY will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$2.47 being high and -$3.20 being low. For ZY, this leads to a yearly average estimate of -$2.92. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Zymergen Inc. surprised analysts by $0.04 when it reported -$0.78 EPS against a consensus estimate of -$0.82. The surprise factor in the prior quarter was $0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.59 and the low estimate is -$0.73. The average estimate for the next quarter is thus -$0.67.
Summary of Insider Activity:
Insiders traded ZY stock several times over the past three months with 1 Buys and 5 Sells. In these transactions, 8,320 shares were bought while 17,216 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 22 over the past year. The total number of shares bought during that period was 1,331,017 while 215,799 shares were sold.